COGT logo

COGT Cogent Biosciences, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$26.71
-1.02 (-3.70%)

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from ad…

Market Cap: $4.65Bwww.cogentbio.com

Price

No data yet.

Social Signal Score

57
5d
—
30d
60
7 mentions
—
60d
59
8 mentions
—
90d
52
13 mentions
—
rss: 7 · news: 4 · 4chan: 2

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 0Buy 10Hold 2Sell 0Strong Sell 0
Avg price target$50.67+89.7%
Low $45Median $52High $55
Current Consensus

Revenue

$0.00-100.00%
$0.00$17.39M$34.78M$52.18M
Sep 2016Sep 2026

Analyst Estimates

FY2025
$-2.27
$-2.56–$-2.05
9 analysts
FY2026
$-2.33
$-2.45–$-2.23
7 analysts
FY2027
$-1.20
$-1.74–$-0.42
9 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Andrew R. Robbins
Sector
Healthcare
Industry
Biotechnology
Employees
258
Beta
0.34
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
5.75
www.cogentbio.com